RESEARCH USE ONLY
10 MG
PT-141
10 MG
Certificate of Analysis
Batch HPLC & MS included
UK Dispatch
Shipped next working day
Research Grade
≥98% documented purity
Discreet Packaging
Plain, secure, tamper-evident
Laboratory Research Use Only: This compound is sold exclusively for qualified in-vitro scientific and laboratory investigation. Strictly not intended for human or veterinary administration.
Product Overview
PT-141 UK | Bremelanotide Research Peptide | 10mg | £14.95
Product Overview
**PT-141 (Bremelanotide)** is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has been investigated for its activity within the melanocortin receptor system.
Unlike compounds that primarily target metabolic or androgen-related pathways, PT-141 acts on melanocortin receptors involved in a range of physiological processes, including aspects of sexual-function signalling.
Scientific interest in PT-141 has centred on its interaction with central nervous system pathways and its potential relevance to research into sexual desire and related biological mechanisms.
Research-Chem.uk provides product information intended to support informed laboratory research and analytical evaluation. The specific identity, purity and composition of the supplied material should be verified against the applicable batch documentation.
**Product specification:** PT-141, 10mg
**Price:** £14.95
What Is PT-141?
PT-141, also known by the scientific name **bremelanotide**, is a synthetic cyclic heptapeptide derived from research into melanocortin signalling.
Melanocortin receptors are part of a receptor family involved in several biological processes, including pigmentation, appetite regulation, energy homeostasis and aspects of sexual function.
PT-141 has attracted particular scientific attention because its pharmacological activity differs from that of conventional hormonal compounds. Rather than acting as a testosterone-like agent, it interacts with melanocortin receptors, including MC3R and MC4R.
Bremelanotide has progressed beyond early laboratory investigation into human clinical research. A prescription formulation, marketed in the United States as Vyleesi, received FDA approval in 2019 for a specific indication involving acquired, generalised hypoactive sexual desire disorder in premenopausal women.
The approved medicine and research-grade PT-141 products should not be considered interchangeable. Their formulation, quality controls, regulatory status and intended uses may differ.
How Is PT-141 Investigated in Research?
Research involving PT-141 has focused on melanocortin receptor activation and the relationship between these receptors and central nervous system signalling.
Areas of scientific investigation include:
- Melanocortin receptor pharmacology
- MC3R and MC4R signalling
- Central nervous system pathways
- Neuroendocrine regulation
- Sexual-function biology
- Peptide structure and receptor interactions
- Pharmacokinetic characteristics
- Peptide stability and analytical characterisation
The mechanisms linking melanocortin receptor activation to changes in sexual desire are not completely understood. Consequently, research findings need to be interpreted within the context of the particular experimental model and formulation investigated.
PT-141 Research Applications
1. Melanocortin Receptor Research
PT-141 provides a research model for investigating the pharmacology of melanocortin receptors.
These receptors participate in multiple physiological pathways, making receptor selectivity, signalling responses and interactions with downstream cellular mechanisms important subjects for further investigation.
2. Central Nervous System Signalling
The melanocortin system is involved in signalling pathways within the central nervous system.
Research into PT-141 has examined how melanocortin receptor activation may relate to neural pathways associated with sexual function and other physiological responses.
These investigations contribute to a broader understanding of peptide-mediated signalling and neuroendocrine regulation.
3. Sexual-Function Research
One of the principal areas associated with PT-141 is research into sexual-function biology.
Clinical studies of prescription bremelanotide have examined changes in sexual desire and associated distress in a defined population of premenopausal women diagnosed with acquired, generalised hypoactive sexual desire disorder.
These results are specific to the studied prescription formulation and clinical setting. They should not be interpreted as evidence that every PT-141 product produces equivalent effects or is suitable for general use.
4. Peptide Pharmacology and Analytical Research
PT-141 is also relevant to research involving synthetic peptide characterisation.
Laboratory investigations may examine peptide identity, purity, molecular characteristics, stability and analytical behaviour under defined experimental conditions.
Reliable analytical documentation is particularly important when evaluating synthetic peptides, as product identity and formulation can affect the interpretation of experimental findings.
What Does the Research Say?
Clinical Research
Bremelanotide has been investigated in controlled clinical trials involving premenopausal women with acquired, generalised hypoactive sexual desire disorder.
Two pivotal Phase III trials evaluated the prescription formulation against placebo over 24 weeks. The studies reported improvements in certain measures of sexual desire and associated distress, although the treatment effects were not universal.
These results supported the approval of Vyleesi in the United States for its specified indication.
Importantly, the approved indication is limited. The medicine is not approved under its US label to treat this condition in men or postmenopausal women, or to enhance sexual performance.
Mechanism of Action
Bremelanotide activates melanocortin receptors. However, the precise mechanism through which this receptor activity translates into clinical changes in sexual desire remains incompletely understood.
This makes PT-141 relevant to ongoing research into receptor-mediated signalling and the neurobiology of sexual function.
Safety Considerations
Clinical research has identified important adverse effects associated with prescription bremelanotide, including nausea, flushing, headache, vomiting and injection-site reactions.
The FDA-approved prescription product also carries warnings concerning temporary increases in blood pressure, reductions in heart rate and focal hyperpigmentation. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease under its US prescribing information.
These findings should be considered when reviewing the compound's pharmacological profile. The safety of an unapproved research-grade product cannot be inferred from clinical trials of a regulated prescription formulation.
PT-141 should therefore be treated as a biologically active investigational peptide when evaluating laboratory research and analytical applications.
Research References
1. FDA — Vyleesi (Bremelanotide) Prescribing Information
**Product:** Vyleesi (bremelanotide injection)
**Initial US approval:** 2019
The official prescribing information describes the compound's pharmacological classification, approved indication, clinical studies, contraindications and safety considerations.
Reference: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
2. FDA — Multidisciplinary Review of Bremelanotide
**Compound:** Bremelanotide / PT-141
**FDA application:** NDA 210557
The FDA review documents the compound's development history, peptide structure, pharmacological classification and clinical-development background.
Reference: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
3. PubChem — Bremelanotide Chemical Information
**Compound:** Bremelanotide
**PubChem CID:** 9941379
**CAS Number:** 189691-06-3
The PubChem record provides chemical identifiers, molecular structure, molecular formula and molecular weight.
Reference: https://pubchem.ncbi.nlm.nih.gov/compound/PT-141
PT-141 Product Specifications
Property Specification
Product Name : PT-141
Alternative Name : Bremelanotide
Compound Class : Synthetic cyclic peptide
Peptide Length : 7 amino acids
Primary Pharmacological Target : Melanocortin receptors
CAS Number : 189691-06-3
PubChem CID : 9941379
Molecular Formula : C₅₀H₆₈N₁₄O₁₀
Molecular Weight : Approximately 1,025.2 g/mol
Product Quantity : 10mg
Listed Price : £14.95
Research Classification : Investigational research peptide
*Chemical identifiers refer to the bremelanotide free-base structure listed by PubChem. The supplied material's exact chemical form should be confirmed through its product documentation.*
Quality and Purity
At Research-Chem.uk, analytical verification and batch traceability are important considerations when evaluating research peptides.
Product-specific documentation should identify the tested material and provide the applicable analytical results, including reported purity where available.
High-performance liquid chromatography (HPLC) is commonly used to assess peptide purity and identify chromatographic components. However, HPLC purity alone does not establish every aspect of identity, potency, sterility or suitability for a particular research application.
Researchers should consult the applicable Certificate of Analysis (COA) for the specific batch rather than relying on general compound descriptions.
Laboratory Research Applications
PT-141 may be of interest to qualified laboratories investigating:
- Melanocortin receptor pharmacology
- MC3R and MC4R signalling
- Peptide structure and characterisation
- Neuroendocrine signalling pathways
- Central nervous system pharmacology
- Sexual-function biology
- Peptide stability and analytical chemistry
- Receptor-mediated biological responses
- Comparative peptide research
All experimental work should follow appropriate laboratory procedures, institutional requirements and applicable regulations.
Why Choose Research-Chem.uk?
Laboratory-Focused Product Information
Our product pages are designed to distinguish chemical identity, scientific background and potential research applications.
Batch Documentation
Product-specific analytical documentation supports traceability and allows researchers to assess the reported characteristics of the supplied material.
Analytical Transparency
HPLC results and other available analytical information should be interpreted within the scope and limitations of the relevant testing method.
Scientifically Accurate Information
We distinguish published clinical findings from laboratory research and avoid treating evidence from a prescription medicine as proof of equivalent effects from an unapproved research product.
Research-Focused Positioning
Research-Chem.uk product information is intended for laboratory and analytical contexts, not as a substitute for medical advice or prescribing information.
Research-Use Disclaimer
**PT-141 is presented for laboratory research and analytical purposes only.**
This product is not intended for human consumption, self-administration, veterinary use, diagnosis, treatment, prevention of disease or use as a dietary supplement.
Although bremelanotide has been approved in a specific prescription formulation in the United States, that approval does not extend automatically to research-grade PT-141 products.
The safety, quality and pharmacological characteristics of an individual research product must be assessed using its own documentation. Published clinical evidence should not be interpreted as establishing the safety or effectiveness of an unapproved formulation.
Researchers are responsible for ensuring that the handling, storage, analysis and disposal of research materials comply with applicable institutional, laboratory and regulatory requirements.
**For laboratory research and analytical purposes only. Not for human or veterinary use.**
| Key Product Features | |
|---|---|
| Product | PT-141 |
| Vial Quantity | 10 MG |
| Purity Threshold | ≥98.0% (HPLC) |
| Physical Form | White lyophilised powder |
| Documentation | Batch-specific Certificate of Analysis (COA) |
| Intended Application | In-vitro scientific laboratory research only |
| Origin / Dispatch | United Kingdom (Shipped next working day) |
PT-141 Product Specifications
| Specification | Details |
|---|---|
| Product Name | PT-141 |
| Stated Purity | ≥98.0% (HPLC) |
| Solvent Matrix | Bacteriostatic or sterile water for injection |
| Appearance | White lyophilised powder |
| Storage Specification | −20 °C long-term; 2–8 °C short-term |
| Testing Method | High-Performance Liquid Chromatography (HPLC) & Mass Spectrometry (MS) |
| Analytical Documentation | Batch-specific Certificate of Analysis (COA) |
| Intended Application | Laboratory research use only (in-vitro) |
Quality and Analytical Standards
At Research-Chem.uk, analytical quality, purity verification, and batch traceability are paramount across our entire research catalogue.
Every batch of PT-141 undergoes rigorous analytical evaluation via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify molecular mass, peptide sequence integrity, and chemical purity. Batch-specific Certificates of Analysis (COA) are provided for qualified laboratory record-keeping and audit compliance.
Our quality-assurance framework guarantees reproducible standards for scientific investigation, analytical assay development, and academic research.
Laboratory Research Applications
PT-141 is supplied exclusively as a reference compound for controlled in-vitro scientific research. Documented experimental applications include:
- In-vitro cellular signalling and biochemical pathway investigations
- Analytical assay validation and high-performance chromatographic reference standardisation
- Receptor binding affinity and enzyme kinetic profiling
- Molecular interaction and quantitative cellular response studies
Strictly not for clinical diagnostic procedures, therapeutic administration, or any form of in-vivo human or veterinary testing.
Why Choose Research-Chem.uk?
HPLC-Verified Purity
Every research compound is verified with chromatographic analysis and supplied with batch-specific purity documentation.
Batch Traceability
Comprehensive documentation and Certificate of Analysis (COA) reports accompany research lots for full experimental reproducibility.
UK Domestic Dispatch
Dispatched directly from within the United Kingdom for reliable, prompt domestic transit in temperature-controlled packaging.
Research-Only Standard
Dedicated strictly to qualified academic, clinical, and industrial research environments.
Transparent Specifications
Full disclosure of molecular weight, CAS registry, purity threshold, and chemical storage recommendations.
Research-Use Disclaimer
For laboratory research use only. Strictly not for human or veterinary administration.
PT-141 supplied by Research-Chem.uk is intended exclusively for in-vitro scientific study, analytical testing, and laboratory evaluation.
This compound is not a medication, drug, medical device, dietary supplement, or cosmetic. It is not approved by regulatory authorities for the diagnosis, treatment, cure, mitigation, or prevention of any disease or condition in humans or animals.
Purchasers are solely responsible for ensuring handling, storage, and laboratory utilization comply with all relevant UK statutory provisions, COSHH assessments, and institutional safety regulations.
